GeneDx Holdings (WGS) Accumulated Expenses (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Accumulated Expenses data on file, last reported at $24.7 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $24.7 million, up 75.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.7 million (up 75.81% YoY), and the FY2025 annual result was $44.7 million, up 258.91% from the prior year.
• Accumulated Expenses fell to $24.7 million in Q1 2026 per WGS's latest filing, from $44.7 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $44.7 million in Q4 2025 and troughed at $7.3 million in Q2 2024.
• A 5-year average of $20.0 million and a median of $18.5 million in 2022 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses tumbled 59.04% in 2024, then jumped 285.52% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $20.3 million in 2022, then tumbled by 40.05% to $12.2 million in 2023, then gained by 2.17% to $12.4 million in 2024, then jumped by 258.91% to $44.7 million in 2025, then sank by 44.79% to $24.7 million in 2026.
• Business Quant data shows WGS's Accumulated Expenses at $24.7 million in Q1 2026, $44.7 million in Q4 2025, and $26.4 million in Q3 2025.